Flowable Hemostats Market Size & Share 2026-2035

Flowable Hemostats Market Size

The global flowable hemostats market was valued at approximately USD 1.08 billion in 2025 and is projected to grow from USD 1.14 billion in 2026 to nearly USD 1.89 billion by 2035, growing at a CAGR of 5.8% during the forecast period, as per the latest report published by Global Market Insights Inc.

The growth of the market is primarily driven by the increasing number of surgical procedures worldwide, rising prevalence of trauma and chronic diseases requiring surgical hemostats, coupled with growing adoption of minimally invasive surgeries.

According to the World Health Organization (WHO), more than 300 million surgical procedures are performed globally every year, highlighting the growing demand for effective surgical bleeding management solutions. In addition, as per studies published in the U.S. National Library of Medicine (NIH/PMC), hemorrhage accounts for nearly 30–40% of trauma-related mortality worldwide, emphasizing the importance of rapid hemostatic control in surgical and trauma settings. Further, the increasing incidence of cardiovascular diseases, orthopedic disorders, cancer surgeries, and traumatic injuries continues to support the demand for advanced flowable hemostatic agents across hospitals and ambulatory surgical centers.

Flowable hemostats are advanced surgical hemostatic agents designed to control bleeding during surgical procedures when conventional techniques such as sutures, cauterization, or manual compression are insufficient. Flowable hemostats are widely used in cardiovascular surgery, neurosurgery, orthopedic surgery, general surgery, gynecological surgery, liver surgery, and trauma care due to their rapid clot formation capabilities and ease of use.

This growth can be attributed to the increasing surgical burden associated with aging populations, rising hospital admissions for trauma and emergency procedures, expanding adoption of minimally invasive surgical techniques, and increasing awareness regarding perioperative blood management. The market also benefited from the significant rebound in surgical procedure volumes following the COVID-19 pandemic, as hospitals globally resumed elective and delayed surgeries that had been postponed during pandemic-related restrictions.

Several major medical device and biotechnology companies are actively contributing to the expansion of the market through product innovation, strategic collaborations, regulatory approvals, and geographic expansion initiatives. Some of the leading players operating in the market include Baxter International, Johnson & Johnson, Pfizer, BD, Integra LifeSciences, and Teleflex Incorporated. These companies continue to strengthen their hemostatic product portfolios through new product launches, advanced biomaterial development, manufacturing expansion, and investments in surgical bleeding management technologies.

Flowable Hemostats Market Trends

Some of the factors that have impacted the market dynamics of the market include the rising focus on managing blood loss during surgery, the rising burden of trauma cases, and constant developments in hemostat products.

• The increasing incidence of trauma injuries and emergency procedures is contributing to market growth. According to the WHO Global Status Report on Road Safety 2023, road traffic crashes kill approximately 1.19 million people annually. These incidents remain the leading cause of death for children and young adults aged 5–29, with 20 to 50 million more people suffering non-fatal injuries.
• Flowable hemostats are increasingly utilized in trauma surgeries and emergency bleeding management due to their rapid clotting capabilities and ease of application in difficult-to-access bleeding sites.
• This industry is also witnessing considerable growth owing to the growing adoption of minimally invasive and robot-assisted surgery procedures. As laparoscopic and robotic surgeries require precise bleeding control, surgeons are increasingly preferring advanced flowable hemostatic products that offer improved handling, targeted application, and faster hemostasis compared to conventional methods.
• Moreover, the constant improvement of technology in the manufacturing of hemostatic products is fueling innovations worldwide. Manufacturers are more concerned about creating synthetic and combined hemostatics that have good biocompatibility, better clotting ability, shorter preparation time, and room temperature storage ability.
• For instance, in 2023, Baxter International launched FLOSEAL + RECOTHROM, the first and only active flowable hemostat with recombinant thrombin, resulting in 1.5 times faster preparation. These advancements are improving product usability across complex surgical specialties.
• Additionally, expanding healthcare infrastructure and increasing adoption of advanced surgical care practices in emerging economies are positively influencing market growth. Rising healthcare expenditure, improving hospital infrastructure, and growing awareness regarding perioperative blood management are supporting broader adoption of flowable hemostats across emerging markets in the Asia Pacific, Latin America, and the Middle East & Africa region, thus supporting the market growth over the forecast period.

Flowable Hemostats Market Analysis

Based on the product type, the flowable hemostats market is segmented into gelatin-based flowable hemostats, collagen-based flowable hemostats, and synthetic polymer-based flowable hemostats. The gelatin-based flowable hemostats segment dominated the market in 2025 and accounted for USD 678 million. The segment is further divided into porcine origin and bovine origin.

• The gelatin-based flowable hemostats are widely used owing to their strong clinical effectiveness, wide surgical applicability, and widespread acceptance in hospital settings.
• Flowable gelatin-based hemostats provide rapid and reliable control of bleeding, adapting easily to irregular wound surfaces and difficult-to-access bleeding sites.
• They are widely used due to their superior handling characteristics, rapid clot formation and ease of application during minimally invasive and open surgical procedures.
• Further, the strong market presence of commercially established products such as FLOSEAL and SURGIFLO, broad surgeon familiarity and favorable clinical outcomes.
• On the other hand, the collagen-based flowable hemostats segment held the second-largest share of 25.8% in 2025, due to the strong hemostatic properties of collagen materials and high biocompatibility. These products are widely used in surgical procedures where rapid platelet activation and effective bleeding control are needed.
• The synthetic polymer-based flowable hemostats segment held a revenue of USD 125 million in 2025. These hemostats offer advantages such as reduced risk of immunogenic reactions, improved room-temperature stability, and longer shelf life compared to biologically derived products. Increasing focus on advanced surgical technologies, minimally invasive procedures, and development of next-generation synthetic sealants and hemostatic agents is expected to support strong future growth of this segment.

Based on the application, the flowable hemostats market is segmented into general surgery, cardiovascular surgery, orthopedic and trauma surgery, gynecological surgery, neurosurgery, plastic and reconstructive surgery, and other applications. The general surgery segment dominated the market with 28.4% of market share in 2025.

• Flowable hemostats have a wide application in various general surgeries, including the abdomen, gastrointestinal tract, colon, bariatric surgery, hepatobiliary surgery, and hernia repair, among others.
• These products offer rapid hemostasis and improve overall surgical efficiency, thereby enhancing surgical outcomes.
• In addition, the increasing number of minimally invasive and laparoscopic general surgery procedures and the rising focus on minimizing intraoperative blood loss and surgical complications continue to increase the demand for advanced flowable hemostatic products.
• Further, the increasing global burden of chronic diseases that require surgical intervention and the rising adoption of advanced surgical bleeding management technologies in hospitals further fuel the growth of the general surgery segment.
• The cardiovascular surgeries segment held a market share of 20.4% in 2025 and is expected to grow at a CAGR of 6.3%. The cardiovascular surgery segment accounted for a significant share of the flowable hemostats market, driven by the high risk of bleeding complications associated with complex cardiac and vascular procedures. The increasing global prevalence of cardiovascular diseases, rising volume of cardiac surgeries, and growing adoption of advanced surgical bleeding management technologies continue to support strong demand for flowable hemostatic products within the cardiovascular surgery segment.
• The orthopedic surgeries segment is expected to witness growth at a CAGR of 5.3% over the analysis timeframe. The increasing number of orthopedic surgeries, fueled by factors such as the rising prevalence of orthopedic disorders, sports injuries, and the aging population, is driving the demand for flowable hemostats.
• For instance, statistics show that in 2022, around 18.6 million orthopedic procedures were performed in the U.S.
• Additionally, advancements in hemostatic agents, such as improved efficacy and reduced risk of adverse effects, are further contributing to their growing adoption in orthopedic surgeries, thus solidifying their market position.

Based on end use, the flowable hemostats market is categorized into hospitals & clinics, ambulatory surgical centers (ASC’s), and other end users. The hospitals & clinics segment dominated the market in 2025 with a revenue of USD 827.2 million and is predicted to grow at a CAGR of 5.7% over the forecast period.

• Hospitals & clinics are the primary location for surgical procedures, where hemostats are used to control bleeding.
• Hospitals & clinics perform a high volume of surgical procedures, from routine general surgeries to complex interventions, which contributes to the high demand for flowable hemostats in these settings.
• Furthermore, the rising incidence of chronic diseases and the growing number of surgical procedures globally are driving the uptake of these hemostats in hospitals and clinics, thus contributing to the segment’s growth.
• Further, the availability of advanced surgical infrastructure, skilled healthcare professionals and increasing adoption of minimally invasive and complex surgical procedures support strong product utilization in hospital settings.
• The ambulatory surgical centers segment is witnessing steady growth at a CAGR of 6% due to the increasing shift toward outpatient and minimally invasive surgical procedures.
• Growing preference for cost-effective outpatient care, expanding ASC infrastructure, and rising adoption of advanced surgical technologies in ACSs are further contributing to segment growth globally.

North America Flowable Hemostats Market

In 2025, North America held a significant share of 40.4% in the global market.

• North America, particularly the U.S., holds a leading position in the global market owing to the high volume of surgical procedures, strong adoption of advanced surgical technologies, and increasing focus on perioperative blood management across healthcare facilities.
• The U.S. flowable hemostats market was valued at USD 346.6 million and USD 363.4 million in 2022 and 2023, respectively. The market size reached approximately USD 397.6 million in 2025, growing from USD 380.5 million in 2024.
• The U.S. has one of the highest healthcare expenditure levels globally, enabling substantial investments in advanced surgical products, operating room technologies, and bleeding management solutions.
• Further, the increasing number of surgical procedures in the region contributes significantly to market demand. According to the American College of Surgeons, approximately 15 million surgical procedures are performed annually in the U.S., supporting strong utilization of flowable hemostatic agents across hospitals and ambulatory surgical centers.
• Similarly, according to the Centers for Disease Control and Prevention (CDC), traumatic injuries account for approximately 40 million emergency department (ED) visits annually in the U.S., significantly increasing demand for rapid bleeding control products during trauma and emergency surgeries.
• Additionally, the growing adoption of minimally invasive surgeries continues to support strong demand for advanced flowable hemostats that offer precise application and improved surgical efficiency.

Europe Flowable Hemostats Market

Europe market accounted for a significant revenue share in 2025 and is anticipated to witness substantial growth over the forecast period.

• The market growth is primarily supported by rising surgical volumes, increasing prevalence of chronic diseases requiring surgical intervention, and growing adoption of advanced hemostatic technologies across the region.
• According to Eurostat, more than 1.1 million cesarean section procedures were performed across Europe in 2023.
• Further, cardiovascular and orthopedic surgeries continue to rise steadily. For instance, as per the OECD data, in 2022, nearly 1 million hip replacements were performed across EU countries (up by about 20% since 2012), and 680,000 knee replacements, significantly supporting demand for intraoperative bleeding management products.
• Additionally, expanding hospital infrastructure, favorable public healthcare coverage, and increasing investments in advanced surgical care continue to support broader access to flowable hemostatic technologies across the region.
• Furthermore, increasing product innovation and availability of advanced biologic and synthetic hemostatic products continue to strengthen long-term market growth across Europe.

Asia Pacific Flowable Hemostats Market

The Asia Pacific market is anticipated to grow at the highest CAGR during the forecast period.

• The growth is primarily attributed to rapidly expanding healthcare infrastructure, increasing surgical procedure volumes, rising healthcare expenditure, and growing awareness regarding advanced surgical bleeding management technologies.
• According to the World Health Organization (WHO), Asia Pacific countries account for a substantial share of global surgical procedures due to large and growing populations, combined with an increasing prevalence of chronic, non-communicable diseases, such as cardiovascular diseases, cancer, neurological disorders, and traumatic injuries.
• This high volume is further driven by rapid aging, as the population aged 65 and older is projected to rise significantly.
• Furthermore, the rising incidence of trauma injuries and road accidents across emerging Asian economies continues to support increasing demand for rapid hemostatic solutions in emergency and trauma care settings.
• Increasing investments in healthcare infrastructure, rising medical tourism, and growing adoption of advanced operating room technologies are further contributing to long-term market expansion throughout Asia Pacific.

Latin America Flowable Hemostats Market

The Latin America market is expected to witness strong growth over the analysis timeframe.

• Countries such as Brazil and Mexico are witnessing increasing investments in healthcare infrastructure, hospital expansion, and surgical care modernization programs, supporting growing adoption of advanced hemostatic products.
• Additionally, rising healthcare expenditure, improving access to minimally invasive surgical procedures, and increasing awareness regarding perioperative blood management are supporting broader adoption of flowable hemostatic agents across Latin America.
• Government initiatives aimed at strengthening healthcare systems and improving access to advanced surgical technologies are further contributing to regional market growth.

Middle East & Africa Flowable Hemostats Market

The Middle East & Africa (MEA) market is experiencing notable growth over the analysis timeframe.

• Increasing prevalence of trauma injuries, rising surgical procedure volumes, and growing investments in healthcare infrastructure are significantly contributing to the growing adoption of flowable hemostatic products across the region.
• The Middle East is also witnessing increasing adoption of minimally invasive surgeries and expansion of specialty surgical centers, which continue to drive utilization of advanced bleeding management products.
• Furthermore, improving healthcare access and growing availability of technologically advanced surgical products are expected to further strengthen the market growth throughout the Middle East & Africa region.

Flowable Hemostats Market Share

The global market is moderately consolidated and highly competitive, with competition driven by the strong presence of multinational medical device companies, surgical technology providers, and specialized hemostatic product manufacturers. Leading companies including Baxter International, Johnson & Johnson, Teleflex Incorporated, Becton, Dickinson and Company (BD), and Integra LifeSciences maintain strong market positions with a collective market share of ~55% through broad surgical product portfolios, extensive hospital relationships, and strong global distribution capabilities.

Market participants primarily compete based on product efficacy, ease of application, clotting speed, biocompatibility, surgeon preference, pricing, and regulatory approvals. Manufacturers are increasingly focusing on the development of advanced flowable hemostatic products with improved handling characteristics, faster preparation time, enhanced tissue adherence, and room-temperature stability to improve surgical efficiency and clinical outcomes.

In addition, growing demand for minimally invasive and robotic-assisted surgeries has encouraged companies to develop next-generation hemostatic agents specifically designed for precise application in confined surgical environments. Companies are also expanding manufacturing capabilities, strengthening strategic partnerships with healthcare providers, and increasing investments in biologic and synthetic hemostatic technologies to strengthen their competitive positioning in the global market.

Flowable Hemostats Market Companies

A few of the prominent players operating in the flowable hemostats industry include:

• Aegis Lifesciences
• Baxter International
• Becton Dickinson and Company (BD)
• Dalim Tissen
• Ethicon (Johnson & Johnson)
• Ferrosan Medical Devices
• Integra LifeSciences Holdings Corporation
• Medcura
• Pfizer
• Teleflex Incorporated
• 3-D Matrix

• Baxter International

Baxter International is a leading player in the global flowable hemostats market, supported by its widely adopted FLOSEAL hemostatic matrix portfolio. The company maintains a strong presence across hospital and surgical care settings through continuous product innovation, advanced bleeding management technologies, and broad utilization of its flowable hemostatic products across multiple surgical specialties.

• Integra LifeSciences Holdings Corporation

Integra LifeSciences offers advanced surgical hemostatic products used across neurosurgery, orthopedic surgery, and general surgery procedures. The company focuses on expanding its surgical technologies portfolio through product innovation, strong hospital partnerships, and increasing adoption of advanced bleeding management solutions in complex surgical applications.

Flowable Hemostats Industry News

• In February 2025, Baxter International launched a room-temperature version of its HEMOPATCH Sealing Hemostat in Europe, designed to improve product accessibility and simplify storage requirements during surgical procedures. This helped the company strengthen its advanced hemostasis portfolio and expand adoption across hospital operating rooms.
• In March 2023, Baxter International Inc. launched FLOSEAL + RECOTHROM, the first active flowable hemostat utilizing recombinant thrombin technology, at the AORN Global Surgical Conference & Expo 2023. This helped the company strengthen its surgical hemostasis portfolio and improve product preparation efficiency.
• In December 2022, Medcura received FDA breakthrough device designation for its LifeGel flowable technology that controls bleeding during surgery for procedures where swelling cannot be tolerated. This helped the company expand its sales in the U.S.

The flowable hemostats market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Gelatin-based flowable hemostats
  • Porcine gelatin
  • Bovine gelatin
• Collagen-based flowable hemostats
• Synthetic polymer-based flowable hemostats

Market, By Application

• General surgery
• Cardiovascular surgery
• Orthopedic and trauma surgery
• Gynecological surgery
• Neurosurgery
• Plastic and reconstructive surgery
• Other applications

Market, By End Use

• Hospitals & clinics
• Ambulatory surgical centers (ASCs)
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE